{"id":4182,"date":"2026-11-10T02:10:00","date_gmt":"2026-11-10T06:10:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4182"},"modified":"2026-11-10T21:12:49","modified_gmt":"2026-11-11T01:12:49","slug":"oyster-raises-60-million-dollars-for-tau-degraders","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4182","title":{"rendered":"Oyster Raises 60 Million Dollars for Tau Degraders"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261110_Oyster_Therapeutics_Deal_and_Financing-768x432.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4191\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261110_Oyster_Therapeutics_Deal_and_Financing-768x432.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261110_Oyster_Therapeutics_Deal_and_Financing-300x169.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261110_Oyster_Therapeutics_Deal_and_Financing-1024x576.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261110_Oyster_Therapeutics_Deal_and_Financing-1536x864.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261110_Oyster_Therapeutics_Deal_and_Financing.png 1672w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Oyster Therapeutics (formerly Kesmalea Therapeutics)<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>Series A financing ($60 million)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Small bifunctional protein degrader (SELFTAC)<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>Undisclosed lead tau degrader<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>Tau<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Alzheimer\u2019s disease and other tauopathies<\/p>\n<h4>Summary<\/h4>\n<p>Oyster Therapeutics, formerly Kesmalea, announced a $60 million Series A led by 4BIO Capital on November 10. Capital is earmarked for an oral brain-penetrant tau degrader and the SELFTAC small bifunctional-degrader platform. Financing is verified; clinical validation is not.<\/p>\n<p>The lead investor released the announcement at 02:10 EST. New investors include Eli Lilly, Actium, CE Ventures and TOHO Ventures, alongside prior investors. The company says proceeds will advance its lead program into clinical development and support platform work. It did not disclose a lead asset code, dosing data, runway, financing split by tranche or a clinical start date.<\/p>\n<h4>Deep Analysis<\/h4>\n<p><strong>Interpretation A:<\/strong> smaller bifunctional degraders might overcome CNS penetration and oral-bioavailability limits seen with larger degraders. The syndicate and $60 million commitment support a credible development effort, but are not pharmacologic proof.<\/p>\n<p><strong>Interpretation B:<\/strong> tau degradation may fail because neuronal exposure, disease-associated selectivity, target turnover and safe partial tau reduction are difficult. The announcement presents a design goal, not measured human brain exposure or target engagement. Unbound brain PK, tau species selectivity, degradation kinetics, off-target proteomics, repeat-dose toxicology, human CSF biomarkers and eventual clinical outcomes will upgrade or falsify the concept.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Oyster is a London-based preclinical company targeting tauopathies, including Alzheimer\u2019s disease. Its SELFTAC approach seeks smaller bifunctional molecules that recruit degradation machinery to tau; the identity of the ligase and clinical candidate were not disclosed in the release.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li>Verified: round amount, stage, lead and participants, rebrand and stated use.<\/li>\n<li>Company claim: oral CNS penetration and pathological-tau selectivity.<\/li>\n<li>Missing: potency, PK\/PD, in-vivo disease modification, manufacturing route, IP boundaries and runway.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>The funding makes a high-risk CNS degrader hypothesis testable. Capital quality should not be confused with proof of therapeutic reach or tau selectivity.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: positive for capitalization, uncertain for therapeutic success. Confidence in Facts: high for investor-announced financing. Confidence in Interpretation: low for CNS translation.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Oyster Therapeutics, formerly Kesmalea, announced a $60 million Series A led by 4BIO Capital on November 10. Capital is earmarked for an oral brain-penetrant tau degrader and the SELFTAC small bifunctional-degrader platform. Financing is&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4191,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[1424,1423,1047],"class_list":["post-4182","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-deals-and-financing","tag-alzheimers-disease-2","tag-oyster-therapeutics","tag-tau"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4182","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4182"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4182\/revisions"}],"predecessor-version":[{"id":4203,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4182\/revisions\/4203"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4191"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4182"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4182"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4182"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}